Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats

Abstract

The efficacy of the combination of the rapid-acting insulin secretagogue mitiglinide and the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin was explored in streptozotocin-nicotinamide-induced type 2 diabetic (STZ-NA) rats and in Zucker fatty (ZF) rats. The STZ-NA rats were prepared at 8 weeks of age. At 9 weeks of age, the combination study was conducted by oral glucose tolerance test (OGTT). At 13 weeks of age, ZF rats were dosed orally with dapagliflozin once daily up to the 22^nd day. At days 15 and 22, the combination study was conducted by OGTT. In 2 different animal models, plasma glucose levels were strongly suppressed by the combination of mitiglinide and dapagliflozin as compared with either drug alone. The urinary glucose excretion was drastically elevated in the dapagliflozin group, but the combination with mitiglinide suppressed it about 50%. In STZ-NA rats, the plasma insulin secretion by the combination of both drugs was about at the same level as in the mitiglinide group. In ZF rats, the plasma insulin secretion by the combination of both drugs was less than mitiglinide group. Thus, in 2 different animal models, the combination of mitiglinide and dapagliflozin showed stronger antihyperglycemic action accompanied by less insulin secretion than mitiglinide alone, and reduced the urinary glucose excretion as compared with dapagliflozin used alone. These results indicate that the combination of mitiglinide and dapagliflozin can be a promising combination for the treatment of diabetic patients.

Key words

mitiglinide - dapagliflozin - glinide - SGLT2 inhibitor

• References

• 1 Whiting D, Guariguata L, Weil C et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011 93: 311-321
• 2 Japan Diabetes Society Treatment Guide for Diabetes 2012–2013
• 3 Ohnota H, Kitamura T, Kinukawa M et al. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Jpn J Pharmacol 1996; 71: 315-323
• 4 Ohnota H, Koizumi T, Tsutsumi N et al. Novel rapid- and short-acting hypoglycemic agent, a calcium(2 s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther 1994; 269: 489-495
• 5 Gregorio F, Ambrosi F, Boemi M et al. Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations. Eur J Pharmacol 2002; 456: 141-147
• 6 Konya H, Katsuno T, Tsunoda T et al. Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2013; 6: 317-325
• 7 Tatsumi F, Hashiramoto M, Hirukawa H et al. Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus. Diabetes Res Clin Pract 2013; 35: 35-44
• 8 Jung JA, Kaku K, Kim JH et al. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus. Adv Ther 2013; 30: 1018-1029
• 9 Kaku K, Inagaki N, Kobayashi N. Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy. Diabetes Ther 2014; in press
• 10 Chen LH, Leung PS. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 392-402
• 11 Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 2012; 12: 230-238
• 12 Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diab Metab Res Rev 2013; 29: 347-356
• 13 Johnsson KM, Ptaszynska A, Schmitz B et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 473-478
• 14 Johnsson KM, Ptaszynska A, Schmitz B et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013; 27: 479-484
• 15 Bolinder J, Ljunggren O, Johansson L et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014; 16: 159-169
• 16 Ichikawa K, Yamato T, Ojima K et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2002; 29: 423-427
• 17 Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729
• 18 Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 13: 1145-1149
• 19 DECODE Study Group . Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405
• 20 Shiraiwa T, Kaneto H, Miyatsuka T et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 2005; 336: 339-345
• 21 Abbatecola AM, Rizzo MR, Barbieri M et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67: 235-240
• 22 Gapstur SM, Gann PH, Lowe W et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283: 2552-2558
• 23 Michaud DS, Fuchs CS, Liu S et al. Dietary glycemic load, carbohydrate, sugar, and colorectal cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2005; 14: 138-147
• 24 Lajous M, Willett W, Lazcano-Ponce E et al. Glycemic load, glycemic index, and the risk of breast cancer among Mexican women. Cancer Causes Control 2005; 16: 1165-1169
• 25 American Diabetes Association . Standards of medical care in diabetes-2014. Diabetes Care 2014; 37: S14-S80
• 26 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596
• 27 Häring HU, Merker L, Seewaldt-Becker E et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36: 3396-3404
• 28 Li L, Yang M, Li Z et al. Efficacy and safety of mitiglinide versus nateglinide in newly diagnosed patients with type 2 diabetes mellitus: a randomized double blind trial. Diabetes Obes Metab 2012; 14: 187-189